Valuation: Aptevo Therapeutics Inc.

Market Cap 5.12M 4.45M 4.16M 3.81M 7.19M 488M 7.32M 49M 19.19M 243M 19.24M 18.81M 803M P/E 2026 *
-0.18x
P/E 2027 * -0.11x
Enterprise Value 5.12M 4.45M 4.16M 3.81M 7.19M 488M 7.32M 49M 19.19M 243M 19.24M 18.81M 803M EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
92.03%
Yield 2026 *
-
Yield 2027 * -
1 week-6.38%
1 month-7.43%
3 months-15.26%
6 months-43.47%
Current year-56.42%
1 week 3.9
Extreme 3.9
4.45
1 month 3.68
Extreme 3.6803
4.9
3 years 3.68
Extreme 3.6803
3,756,772.8
5 years 3.68
Extreme 3.6803
12,940,587.79
10 years 3.68
Extreme 3.6803
52,102,512
Manager TitleAgeSince
Chief Executive Officer 60 2026-03-31
Director of Finance/CFO 59 2023-03-02
Chief Tech/Sci/R&D Officer - 2026-05-27
Director TitleAgeSince
Chairman 64 2026-03-31
Director/Board Member 60 2026-03-31
Director/Board Member 71 2016-07-31
Change 5-day change 1-year change 3-year change Capi.($)
-3.10%-6.65%-91.82%-100.00% 5.12M
+0.05%+2.80%+38.17%+74.12% 56.54B
-3.06%-8.56%+22.91%+58.73% 53.6B
+2.61%+3.03%-14.71%-12.00% 22.91B
-0.95%-7.19%-12.62%+338.85% 21.37B
+0.15%-0.77%+23.76%-11.52% 20.27B
-0.67%-3.25%+30.55%-29.84% 17.56B
-1.45%-7.24%+17.67%+563.14% 14.75B
+9.91%+2.64%+188.84%+326.19% 13.53B
+2.75%-3.51%+46.29%+159.39% 13.33B
Average +1.04%-1.88%+24.91%+136.71% 25.98B
Weighted average by Cap. +0.12%-1.70%+30.92%+121.40%

Financials

2026 *2027 *
Net sales - -
Net income -27.86M -24.21M -22.6M -20.75M -39.13M -2.66B -39.81M -267M -104M -1.32B -105M -102M -4.37B -29.4M -25.55M -23.85M -21.9M -41.29M -2.8B -42.01M -281M -110M -1.4B -110M -108M -4.61B
Net Debt - -
Logo Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel bispecific immunotherapies for the treatment of cancer. The Company has two clinical candidates: Mipletamig and ALG.APV-527. Mipletamig is being evaluated in RAINIER, a two-part Phase 1b/2 trial for the treatment of frontline acute myeloid leukemia in combination with standard-of-care venetoclax + azacitidine. Mipletamig has received orphan drug designation for AML according to the Orphan Drug Act. ALG.APV-527, a bispecific conditional 4-1BB agonist, only active upon simultaneous binding to 4-1BB and 5T4, is being co-developed with Alligator Bioscience and is being evaluated in a Phase 1 clinical trial for the treatment of multiple solid tumor types likely to express 5T4. The Company has three pre-clinical candidates with different mechanisms of action designed to target a range of solid tumors. All pipeline candidates are created from two proprietary platforms, ADAPTIR and ADAPTIR-FLEX.
Employees
-
Date Price Change Volume
26-08-03 US$3.983 -3.10% 7,367
26-07-31 US$4.110 -0.48% 10,339
26-07-30 US$4.130 +3.77% 11,189
26-07-29 US$3.980 -5.46% 23,178
26-07-28 US$4.210 0.00% 7,912
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
4.110USD
Average target price
25.50USD
Spread / Average Target
+520.44%

Quarterly revenue - Rate of surprise